Novel Staging Schemes for Siewert Type II Esophagogastric Junction Adenocarcinoma: A Real-World Data Cohort Study From SEER Database

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05419349

Enrollment

1819

Registered

2022-06-15

Start date

2022-06-01

Completion date

2022-06-07

Last updated

2022-11-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the Esophagogastric Junction

Keywords

esophagogastric junction, total examined lymph nodes, staging

Brief summary

This study have two aims, the first is to explore the optimal cutoff of TLN for Siewert type II AEG using the Surveillance, Epidemiology, and End Results (SEER) database the second is to provide a more accurate staging for Siewert type II AEG patients.

Interventions

PROCEDUREesophagogastric junction cancer surgery

esophagogastric junction cancer surgery

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

Siewert type for adenocarcinoma of the esophagogastric junction; pathologically confirmed T1-4aN0-3M0 stage after surgery after a pathological examination of the LNs.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	5-year overall survival	the time from disease diagnosis to death from any cause

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026